Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Chile | 62.0 | 63.8 | 44.2 | 33.6 | 41.2 | 44.3 | | 29.9 |
| Spain | 22.5 | 22.7 | 16.9 | 18.7 | 18.2 | 18.3 | | 16.6 |
| Israel | 3.8 | 3.6 | 4.3 | 8.8 | 9.5 | 14.0 | | 18.1 |
| Mexico | 14.5 | 11.0 | 7.9 | 8.0 | 5.6 | 4.6 | | 3.7 |
| Other | 901.3 | 1,673.7 | 1,362.2 | 832.7 | 915.8 | 884.9 | | 423.5 |
| Total revenues [+] | 1,004.2 | 1,774.7 | 1,435.4 | 901.9 | 990.3 | 966.0 | 1,117.5 | 491.7 |
| Products | | | | | | | | 80.1 |
| Services | | | | | | | | 329.7 |
| Revenue growth [+] | -43.4% | 23.6% | 59.1% | -8.9% | 2.5% | -13.6% | 127.3% | 439.6% |
| Chile | -2.7% | 44.5% | 31.2% | -18.4% | -6.9% | | | 2.5% |
| Spain | -0.9% | 34.0% | -9.7% | 3.0% | -0.5% | | | -22.0% |
| Israel | 7.9% | -16.2% | -51.5% | -7.5% | -32.1% | | | -12.3% |
| Mexico | 32.2% | 39.9% | -2.1% | 43.5% | 21.6% | | | -36.8% |
| Pharmaceutical | | | | | | | | 4.1% |
| Cost of goods sold [+] | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 235.2 |
| Cost of product sales | | | | | | | | 41.9 |
| Cost of services | | | | | | | | 193.3 |
| Gross profit | 1,004.2 | 1,774.7 | 1,435.4 | 901.9 | 990.3 | 966.0 | 1,117.5 | 256.5 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 52.2% |
| Selling, general and administrative | 372.7 | 468.9 | 355.6 | 343.3 | 358.3 | 414.6 | 407.3 | 196.6 |
| Research and development | 73.9 | 76.9 | 75.3 | 117.9 | 125.6 | 126.4 | 113.9 | 99.5 |
| Equity in earnings | -0.4 | -0.6 | -0.5 | -2.9 | | | -7.7 | -7.1 |
| Other operating expenses | 802.4 | 1,241.8 | 946.8 | 622.4 | 655.8 | 688.2 | 692.8 | 58.9 |
| EBITDA [+] | -136.5 | 65.3 | 142.6 | -90.7 | -52.1 | -161.2 | -7.6 | -63.3 |
| EBITDA growth | -309.0% | -54.2% | -257.1% | 74.3% | -67.7% | 2013.0% | -88.0% | -48.3% |
| EBITDA margin | -13.6% | 3.7% | 9.9% | -10.1% | -5.3% | -16.7% | -0.7% | -12.9% |
| Depreciation | 20.9 | 28.4 | 29.0 | 29.0 | 29.4 | 30.6 | 32.2 | 14.3 |
| EBITA | -157.4 | 36.9 | 113.6 | -119.8 | -81.5 | -191.8 | -39.8 | -77.6 |
| EBITA margin | -15.7% | 2.1% | 7.9% | -13.3% | -8.2% | -19.9% | -3.6% | -15.8% |
| Amortization of intangibles | 87.8 | 50.3 | 56.4 | 64.8 | 67.9 | 71.5 | 64.4 | 28.0 |
| EBIT [+] | -245.2 | -13.4 | 57.2 | -184.6 | -149.4 | -263.2 | -104.2 | -105.6 |
| EBIT growth | 1731.6% | -123.4% | -131.0% | 23.5% | -43.2% | 152.6% | -1.3% | -23.1% |
| EBIT margin | -24.4% | -0.8% | 4.0% | -20.5% | -15.1% | -27.3% | -9.3% | -21.5% |
| Non-recurring items | -18.6 | -31.5 | | 92.4 | 21.8 | 13.2 | | |
| Interest expense, net [+] | 10.1 | 18.9 | 21.8 | 19.8 | 10.7 | 6.0 | 7.0 | 8.2 |
| Interest expense | 12.1 | 18.9 | 21.9 | 21.5 | 11.9 | 6.6 | 7.4 | 8.4 |
| Interest income | 2.0 | 0.0 | 0.2 | 1.7 | 1.2 | 0.6 | 0.5 | 0.3 |
| Other income (expense), net [+] | -154.8 | -13.3 | 13.2 | -8.2 | 4.6 | 10.5 | 14.3 | -24.2 |
| Unrealized gain/loss on derivatives | 0.6 | 0.8 | 0.1 | 0.2 | 3.0 | 0.1 | 2.8 | -39.1 |
| Change in value of contingent liability | -1.3 | -1.7 | -4.0 | -14.9 | -16.8 | -3.4 | 17.0 | 5.1 |
| Other | -155.8 | -14.8 | 12.7 | -11.3 | 1.5 | 10.5 | 3.9 | 7.7 |
| Pre-tax income | -391.5 | -14.0 | 48.7 | -305.0 | -177.3 | -271.9 | -96.8 | -138.0 |
| Income taxes | -63.5 | 15.5 | 17.6 | 7.1 | 38.7 | -18.9 | -56.1 | -113.7 |
| Tax rate | 16.2% | | 36.2% | | | 6.9% | 58.0% | 82.4% |
| Minority interest | | | | | | | | -1.4 |
| Net income | -328.4 | -30.1 | 30.6 | -314.9 | -153.0 | -305.3 | -48.4 | -30.0 |
| Net margin | -32.7% | -1.7% | 2.1% | -34.9% | -15.5% | -31.6% | -4.3% | -6.1% |
| |
| Basic EPS [+] | ($0.46) | ($0.05) | $0.05 | ($0.53) | ($0.27) | ($0.55) | ($0.09) | ($0.06) |
| Growth | 881.9% | -197.4% | -109.0% | 94.6% | -50.2% | 521.8% | 42.7% | -84.9% |
| Diluted EPS [+] | ($0.46) | ($0.05) | $0.05 | ($0.53) | ($0.27) | ($0.55) | ($0.09) | ($0.06) |
| Growth | 881.9% | -197.4% | -109.0% | 94.6% | -50.2% | 527.2% | 41.5% | -84.9% |
| |
| Shares outstanding (basic) [+] | 719.1 | 648.1 | 640.7 | 595.5 | 563.1 | 559.2 | 550.8 | 488.1 |
| Growth | 11.0% | 1.2% | 7.6% | 5.7% | 0.7% | 1.5% | 12.9% | 15.7% |
| Shares outstanding (diluted) [+] | 719.1 | 648.1 | 640.7 | 595.5 | 563.1 | 559.2 | 555.6 | 488.1 |
| Growth | 11.0% | 1.2% | 7.6% | 5.7% | 0.7% | 0.6% | 13.8% | 15.7% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|